Login to Your Account

AtheroGenics Soars 64 Percent On AGI-1067 Phase IIb Results

By Aaron Lorenzo

Wednesday, September 29, 2004
AtheroGenics Inc. saw its share value skyrocket on positive clinical trial results that revealed its lead drug candidate cut plaque buildup in heart disease patients. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription